首页 > 最新文献

Doklady Biochemistry and Biophysics最新文献

英文 中文
Study of Radiosensitivity and Induction of Radiation Adaptive Response in Peripheral Blood Lymphocytes of Patients with Oncological Diseases Using the Micronuclear Test 利用微核试验研究肿瘤疾病患者外周血淋巴细胞的辐射敏感性和辐射适应性反应诱导。
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-18 DOI: 10.1134/S1607672924600362
V. E. Balakin, O. M. Rozanova, N. S. Strelnikova, E. N. Smirnova, T. A. Belyakova

Radiosensitivity to low and medium doses of X-ray radiation and the ability to induce a radiation adaptive response (RAR) of lymphocytes during in vitro irradiation of peripheral blood of patients with cancer were studied. The criterion for cytogenetic damage was the frequency of micronuclei (MN) in cytochalasin-blocked binucleate lymphocytes in culture. It was found that the spontaneous level of cytogenetic damage in the lymphocytes of patients was 2.6 times higher than in healthy volunteers, and there was also significant interindividual variability in values compared to the control cohort. There were no differences in mean values for radiosensitivity to low and medium doses of X-ray between the study groups. There was no correlation between the spontaneous level of MN in lymphocytes and the radiosensitivity of individuals in both groups. RAR was induced with the same frequency and to the same extent in lymphocytes from both patients and healthy individuals.

研究了低剂量和中等剂量 X 射线辐射的放射敏感性,以及体外照射癌症患者外周血时诱导淋巴细胞产生辐射适应反应(RAR)的能力。细胞遗传损伤的标准是细胞松素阻断培养的双核淋巴细胞中出现微核(MN)的频率。研究发现,患者淋巴细胞中细胞遗传损伤的自发水平是健康志愿者的 2.6 倍,与对照组相比,个体间的数值差异也很大。研究组之间对低剂量和中等剂量 X 射线辐射敏感性的平均值没有差异。淋巴细胞中 MN 的自发水平与两组个体的辐射敏感性之间没有相关性。患者和健康人的淋巴细胞诱导 RAR 的频率和程度相同。
{"title":"Study of Radiosensitivity and Induction of Radiation Adaptive Response in Peripheral Blood Lymphocytes of Patients with Oncological Diseases Using the Micronuclear Test","authors":"V. E. Balakin,&nbsp;O. M. Rozanova,&nbsp;N. S. Strelnikova,&nbsp;E. N. Smirnova,&nbsp;T. A. Belyakova","doi":"10.1134/S1607672924600362","DOIUrl":"10.1134/S1607672924600362","url":null,"abstract":"<p>Radiosensitivity to low and medium doses of X-ray radiation and the ability to induce a radiation adaptive response (RAR) of lymphocytes during in vitro irradiation of peripheral blood of patients with cancer were studied. The criterion for cytogenetic damage was the frequency of micronuclei (MN) in cytochalasin-blocked binucleate lymphocytes in culture. It was found that the spontaneous level of cytogenetic damage in the lymphocytes of patients was 2.6 times higher than in healthy volunteers, and there was also significant interindividual variability in values compared to the control cohort. There were no differences in mean values for radiosensitivity to low and medium doses of X-ray between the study groups. There was no correlation between the spontaneous level of MN in lymphocytes and the radiosensitivity of individuals in both groups. RAR was induced with the same frequency and to the same extent in lymphocytes from both patients and healthy individuals.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141632301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Study of TRPV1 Channels of the Central Nervous System and Their Effect on Anxiety in ICR Mice 中枢神经系统 TRPV1 通道及其对 ICR 小鼠焦虑症影响的研究
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-18 DOI: 10.1134/S1607672924600325
V. M. Pavlov, A. Yu. Fedotova, Y. A. Andreev, V. A. Palikov, I. A. Dyachenko

The TRPV1 channel is actively involved in various neuronal processes and is found in various structures of the nervous system, including peripheral and central neurons, sensory ganglia, spinal cord, and various parts of the brain. Due to its ability to respond to various stimuli, TRPV1 can have a significant impact on the body’s responses to stress. Studies indicate the involvement of TRPV1 in the regulation of anxiety behavior. Suppression of TRPV1 activity leads to a decrease in the level of anxiety in animals, which indicates the importance of this channel in psychoemotional regulation. A promising compound for inhibiting this channel is the APHC3 peptide, which is a selective receptor antagonist. The results obtained this study show that this peptide has a pronounced anxiolytic effect, reducing the level of anxiety in the studied animals.

TRPV1 通道积极参与各种神经元过程,存在于神经系统的各种结构中,包括外周和中枢神经元、感觉神经节、脊髓和大脑的各个部分。由于 TRPV1 能够对各种刺激做出反应,因此它对人体对压力的反应有重大影响。研究表明,TRPV1 参与了焦虑行为的调节。抑制 TRPV1 的活性可降低动物的焦虑水平,这表明该通道在心理情绪调节中的重要性。APHC3 肽是一种有前景的抑制该通道的化合物,它是一种选择性受体拮抗剂。这项研究的结果表明,这种肽具有明显的抗焦虑作用,能降低研究动物的焦虑程度。
{"title":"The Study of TRPV1 Channels of the Central Nervous System and Their Effect on Anxiety in ICR Mice","authors":"V. M. Pavlov,&nbsp;A. Yu. Fedotova,&nbsp;Y. A. Andreev,&nbsp;V. A. Palikov,&nbsp;I. A. Dyachenko","doi":"10.1134/S1607672924600325","DOIUrl":"10.1134/S1607672924600325","url":null,"abstract":"<p>The TRPV1 channel is actively involved in various neuronal processes and is found in various structures of the nervous system, including peripheral and central neurons, sensory ganglia, spinal cord, and various parts of the brain. Due to its ability to respond to various stimuli, TRPV1 can have a significant impact on the body’s responses to stress. Studies indicate the involvement of TRPV1 in the regulation of anxiety behavior. Suppression of TRPV1 activity leads to a decrease in the level of anxiety in animals, which indicates the importance of this channel in psychoemotional regulation. A promising compound for inhibiting this channel is the APHC3 peptide, which is a selective receptor antagonist. The results obtained this study show that this peptide has a pronounced anxiolytic effect, reducing the level of anxiety in the studied animals.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141632302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proinflammatory Activation of Monocytes in Patients with Immunoinflammatory Rheumatic Diseases 免疫炎症性风湿病患者单核细胞的促炎性激活。
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-13 DOI: 10.1134/S1607672924700959
A. I. Bogatyreva, E. V. Gerasimova, T. V. Kirichenko, Yu. V. Markina, T. V. Popkova, M. V. Shalygina, T. V. Tolstik, A. M. Markin, A. N. Orekhov

The pathogenesis of immunoinflammatory rheumatic diseases (IRDs) is based on chronic inflammation, one of the key mechanisms of which may be abnormal activation of macrophages, leading to further disruption of the immune system.

. The objective of this study was to evaluate the proinflammatory activation of circulating monocytes in patients with IRDs.

. The study involved 149 participants (53 patients with rheumatoid arthritis (RA), 45 patients with systemic lupus erythematosus (SLE), 34 patients with systemic scleroderma (SSc), and 17 participants without IRDs) 30 to 65 years old. Basal and lipopolysaccharide (LPS)-stimulated secretion of monocytes was studied in a primary culture of monocytes obtained from blood by immunomagnetic separation. Quantitative assessment of the cytokines tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β), as well as the chemokine monocyte chemoattractant protein-1 (MCP-1) was carried out in the culture fluid by ELISA. Proinflammatory activation of monocytes was calculated as the ratio of LPS-stimulated and basal secretions.

. It was shown that the basal secretion of all studied cytokines was significantly increased in all groups of patients with IRDs, except for the secretion of IL-1β in the SLE group, compared to the control. LPS-stimulated secretion of TNF-α was increased and MCP-1 was decreased in patients with IRDs compared to the control group; LPS-stimulated IL-1β secretion only in the SSc group significantly differed from the control group. In the RA group, monocyte activation was reduced for all cytokines compared to the control; in the SLE group, for TNF-α and MCP-1; in the SSc group, for MCP-1.

. The decrease in proinflammatory activation of monocytes in patients with IRDs is due to a high level of basal secretion of cytokines, which can lead to disruption of the adequate immune response in these diseases and is an important link in the pathogenesis of chronic inflammation.

免疫炎症性风湿病(IRDs)的发病机制以慢性炎症为基础,其关键机制之一可能是巨噬细胞的异常激活,从而导致免疫系统的进一步破坏。本研究的目的是评估 IRD 患者循环单核细胞的促炎症激活情况。这项研究涉及 149 名 30 至 65 岁的参与者(53 名类风湿性关节炎(RA)患者、45 名系统性红斑狼疮(SLE)患者、34 名系统性硬皮病(SSc)患者和 17 名无 IRD 患者)。通过免疫磁性分离从血液中获得的单核细胞原代培养物,对单核细胞的基础分泌和脂多糖(LPS)刺激分泌进行了研究。通过 ELISA 方法对培养液中的细胞因子肿瘤坏死因子α(TNF-α)、白细胞介素 1β(IL-1β)以及趋化因子单核细胞趋化蛋白-1(MCP-1)进行了定量评估。以 LPS 刺激分泌物与基础分泌物之比计算单核细胞的促炎活化。结果表明,与对照组相比,除系统性红斑狼疮组 IL-1β 的分泌外,所有研究细胞因子的基础分泌在所有 IRD 患者组中都显著增加。与对照组相比,IRDs 患者在 LPS 刺激下 TNF-α 的分泌增加,MCP-1 的分泌减少;只有 SSc 组在 LPS 刺激下 IL-1β 的分泌与对照组有明显差异。与对照组相比,RA 组单核细胞活化的所有细胞因子均减少;SLE 组单核细胞活化的 TNF-α 和 MCP-1 均减少;SSc 组单核细胞活化的 MCP-1 减少。IRD患者的单核细胞促炎激活减少是由于细胞因子的基础分泌水平较高,这会导致这些疾病的适当免疫反应被破坏,是慢性炎症发病机制中的一个重要环节。
{"title":"Proinflammatory Activation of Monocytes in Patients with Immunoinflammatory Rheumatic Diseases","authors":"A. I. Bogatyreva,&nbsp;E. V. Gerasimova,&nbsp;T. V. Kirichenko,&nbsp;Yu. V. Markina,&nbsp;T. V. Popkova,&nbsp;M. V. Shalygina,&nbsp;T. V. Tolstik,&nbsp;A. M. Markin,&nbsp;A. N. Orekhov","doi":"10.1134/S1607672924700959","DOIUrl":"10.1134/S1607672924700959","url":null,"abstract":"<p>The pathogenesis of immunoinflammatory rheumatic diseases (IRDs) is based on chronic inflammation, one of the key mechanisms of which may be abnormal activation of macrophages, leading to further disruption of the immune system.</p><p>. The objective of this study was to evaluate the proinflammatory activation of circulating monocytes in patients with IRDs.</p><p>. The study involved 149 participants (53 patients with rheumatoid arthritis (RA), 45 patients with systemic lupus erythematosus (SLE), 34 patients with systemic scleroderma (SSc), and 17 participants without IRDs) 30 to 65 years old. Basal and lipopolysaccharide (LPS)-stimulated secretion of monocytes was studied in a primary culture of monocytes obtained from blood by immunomagnetic separation. Quantitative assessment of the cytokines tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β), as well as the chemokine monocyte chemoattractant protein-1 (MCP-1) was carried out in the culture fluid by ELISA. Proinflammatory activation of monocytes was calculated as the ratio of LPS-stimulated and basal secretions.</p><p>. It was shown that the basal secretion of all studied cytokines was significantly increased in all groups of patients with IRDs, except for the secretion of IL-1β in the SLE group, compared to the control. LPS-stimulated secretion of TNF-α was increased and MCP-1 was decreased in patients with IRDs compared to the control group; LPS-stimulated IL-1β secretion only in the SSc group significantly differed from the control group. In the RA group, monocyte activation was reduced for all cytokines compared to the control; in the SLE group, for TNF-α and MCP-1; in the SSc group, for MCP-1.</p><p>. The decrease in proinflammatory activation of monocytes in patients with IRDs is due to a high level of basal secretion of cytokines, which can lead to disruption of the adequate immune response in these diseases and is an important link in the pathogenesis of chronic inflammation.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The 3,3'-dimethoxy-4,4'-dihydroxy-stilbene Triazole (STT) Inhibits Liver Cancer Cell Growth by Targeting Akt/mTOR Pathway 3,3'-二甲氧基-4,4'-二羟基二苯乙烯三唑(STT)通过靶向 Akt/mTOR 通路抑制肝癌细胞生长
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-13 DOI: 10.1134/S1607672923600537
Meng Sun, Jiangtao Bai, Haisong Wang, Long Zhou, Shanfeng Li

The present study was aimed to investigate the proliferation inhibitory ability of 3,3'-dimethoxy-4,4'-dihydroxy-stilbene triazole (STT) on SNU449 and Huh7 cells. Moreover, the mechanism associated with the suppression of liver cancer cell proliferation by STT was also studied. The results revealed that STT suppresses proliferation of SNU449 and Huh7 cells to 28 and 21%, respectively treatment with 20 µM. The clonogenic survival of SNU449 and Huh7 cells was also significantly reduced after incubation with STT compared to the control cultures. In comparison to the control, STT treatment significantly decreased the invasive potential of SNU449 cells. Treatment with STT led to a prominent suppression in p62 and increase in LC3B protein expression in SNU449 cells compared to the control cells. The STT treatment dramatically decreased p-Akt and p-mTOR protein expression in SNU449 cells. Docking study revealed that STT interacts via traditional hydrogen bonding with the glutamine, phenylalanine, leucine, serine, arginine, aspartic acid, and lysine residues of Akt protein. In summary, the current study demonstrates that STT effectively suppresses the viability of SNU449 and Huh7 liver cancer cells. Moreover, STT treatment of the liver cancer cells also significantly reduces the clonogenic survival and invasive potential of SNU449 cells. Treatment of liver cancer cells with STT increases the expression of autophagic, targets anti-autophagic protein expression and down-regulates Akt/mTOR pathway to inhibit cancer growth and proliferation. Thus, STT exhibits prominent anticancer effect and needs to be investigated further as a potential candidate for the treatment of liver cancer.

本研究旨在探讨 3,3'-二甲氧基-4,4'-二羟基二苯乙烯三唑(STT)对 SNU449 和 Huh7 细胞的增殖抑制能力。此外,还研究了 STT 抑制肝癌细胞增殖的相关机制。结果显示,STT 在 20 µM 的浓度下可将 SNU449 和 Huh7 细胞的增殖率分别抑制 28% 和 21%。与对照组相比,SNU449 和 Huh7 细胞在 STT 培养后的克隆存活率也明显降低。与对照组相比,STT 处理明显降低了 SNU449 细胞的侵袭潜力。与对照组相比,STT 处理可明显抑制 SNU449 细胞中 p62 蛋白的表达,增加 LC3B 蛋白的表达。STT 处理可显著降低 SNU449 细胞中 p-Akt 和 p-mTOR 蛋白的表达。对接研究显示,STT 通过传统的氢键与 Akt 蛋白的谷氨酰胺、苯丙氨酸、亮氨酸、丝氨酸、精氨酸、天冬氨酸和赖氨酸残基相互作用。综上所述,本研究表明 STT 能有效抑制 SNU449 和 Huh7 肝癌细胞的活力。此外,用 STT 处理肝癌细胞还能显著降低 SNU449 细胞的克隆存活率和侵袭潜力。用 STT 处理肝癌细胞可增加自噬的表达、靶向抗自噬蛋白的表达并下调 Akt/mTOR 通路,从而抑制癌症的生长和增殖。因此,STT 具有显著的抗癌作用,作为治疗肝癌的潜在候选药物,有待进一步研究。
{"title":"The 3,3'-dimethoxy-4,4'-dihydroxy-stilbene Triazole (STT) Inhibits Liver Cancer Cell Growth by Targeting Akt/mTOR Pathway","authors":"Meng Sun,&nbsp;Jiangtao Bai,&nbsp;Haisong Wang,&nbsp;Long Zhou,&nbsp;Shanfeng Li","doi":"10.1134/S1607672923600537","DOIUrl":"10.1134/S1607672923600537","url":null,"abstract":"<p>The present study was aimed to investigate the proliferation inhibitory ability of 3,3'-dimethoxy-4,4'-dihydroxy-stilbene triazole (STT) on SNU449 and Huh7 cells. Moreover, the mechanism associated with the suppression of liver cancer cell proliferation by STT was also studied. The results revealed that STT suppresses proliferation of SNU449 and Huh7 cells to 28 and 21%, respectively treatment with 20 µM. The clonogenic survival of SNU449 and Huh7 cells was also significantly reduced after incubation with STT compared to the control cultures. In comparison to the control, STT treatment significantly decreased the invasive potential of SNU449 cells. Treatment with STT led to a prominent suppression in p62 and increase in LC3B protein expression in SNU449 cells compared to the control cells. The STT treatment dramatically decreased p-Akt and p-mTOR protein expression in SNU449 cells. Docking study revealed that STT interacts <i>via</i> traditional hydrogen bonding with the glutamine, phenylalanine, leucine, serine, arginine, aspartic acid, and lysine residues of Akt protein. In summary, the current study demonstrates that STT effectively suppresses the viability of SNU449 and Huh7 liver cancer cells. Moreover, STT treatment of the liver cancer cells also significantly reduces the clonogenic survival and invasive potential of SNU449 cells. Treatment of liver cancer cells with STT increases the expression of autophagic, targets anti-autophagic protein expression and down-regulates Akt/mTOR pathway to inhibit cancer growth and proliferation. Thus, STT exhibits prominent anticancer effect and needs to be investigated further as a potential candidate for the treatment of liver cancer.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Manifestations and Prognosis of Giant Cell Arteritis: A Retrospective Cohort Study 巨细胞动脉炎的临床表现和预后:一项回顾性队列研究
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-13 DOI: 10.1134/S1607672924700984
E. E. Fedorinova, N. M. Bulanov, A. D. Meshkov, O. O. Borodin, I. O. Smitienko, E. V. Chachilo, A. A. Nartov, A. L. Filatova, A. V. Naumov, P. I. Novikov, S. V. Moiseev

The aim of the study was to evaluate the clinical manifestations and survival of patients with giant cell arteritis (GCA).

. A retrospective study included 166 patients with newly diagnosed GCA. Clinical, laboratory, and instrumental data and three sets of classification criteria were used to confirm the diagnosis: the American College of Rheumatology (ACR) 1990, the revised ACR criteria of 2016 and/or the new ACR and European Alliance of Rheumatologic Associations (EULAR) 2022 criteria. Some of the patients underwent instrumental investigations: temporal artery ultrasound Doppler (n = 61), contrast-enhanced computed tomography (n = 5), CT angiography (n = 6), magnetic resonance imaging (n = 4), MR angiography (n = 3), and 18F-FDG PET/CT (n = 47). Overall and recurrence-free survival rates were analyzed using survival tables and Kaplan–Meier method.

. The most frequent first manifestations of GCA were headache (81.8%), weakness (64%), fever (63.8%), and symptoms of rheumatic polymyalgia (56.6%). Changes in temporal arteries in color duplex scanning were detected in 44 out of 61 patients. GCs therapy was performed in all patients who agreed to be treated (n = 158), methotrexate was used in 49 out of 158 patients, leflunomide in 9 patients. In 45 (28.5%) out of 158 patients, a stable remission was achieved as a result of GC monotherapy; in 120 (75.9%) patients, long-term maintenance therapy with GCs was required to prevent exacerbations, including 71 (44.9%) patients in combination with methotrexate or other immunosuppressive drugs. The follow-up period of patients with a history of relapses was 21.0 (8.0–54.0) months. Relapses developed in 73 (46.2%) patients. The overall one-year survival rate was 97.1% [95% CI 94.3; 99.9], and the five-year survival rate of patients was 94.6% [95% CI 90.2; 99.0]. The one-year relapse-free survival rate was 86.4% [95% CI 80.5; 92.3], and the five-year relapse-free survival rate was 52.4% [95% CI 42.0; 62.8]. Twelve (7.2%) of 166 patients died. The cause of death was myocardial infarction in two patients, stroke in two patients, and breast cancer in one patient; in the remaining seven cases, the cause of death was not determined.

Given the high frequency of disease exacerbation, patients with GCA require long-term follow-up, especially during the first year after diagnosis.

研究旨在评估巨细胞动脉炎(GCA)患者的临床表现和存活率。一项回顾性研究纳入了 166 名新确诊的 GCA 患者。临床、实验室和仪器数据以及三套分类标准用于确诊:美国风湿病学会(ACR)1990 年标准、2016 年修订版 ACR 标准和/或 ACR 和欧洲风湿病学协会联盟(EULAR)2022 年新标准。部分患者接受了仪器检查:颞动脉超声多普勒(61例)、对比增强计算机断层扫描(5例)、CT血管造影(6例)、磁共振成像(4例)、MR血管造影(3例)和18F-FDG PET/CT(47例)。采用生存表和 Kaplan-Meier 法分析总生存率和无复发生存率。GCA最常见的首发症状是头痛(81.8%)、乏力(64%)、发热(63.8%)和风湿性多肌痛症状(56.6%)。61 名患者中有 44 人在彩色双相扫描中发现颞动脉发生变化。所有同意接受治疗的患者(158 人)都接受了转基因药物治疗,158 名患者中有 49 人使用了甲氨蝶呤,9 人使用了来氟米特。在 158 例患者中,有 45 例(28.5%)患者在接受 GC 单一疗法后病情得到稳定缓解;有 120 例(75.9%)患者需要长期接受 GCs 维持疗法以防止病情恶化,其中 71 例(44.9%)患者与甲氨蝶呤或其他免疫抑制剂联合使用。有复发史的患者的随访时间为 21.0(8.0-54.0)个月。73例(46.2%)患者复发。总的一年生存率为97.1% [95% CI 94.3; 99.9],五年生存率为94.6% [95% CI 90.2; 99.0]。一年无复发生存率为86.4% [95% CI 80.5; 92.3],五年无复发生存率为52.4% [95% CI 42.0; 62.8]。166名患者中有12人(7.2%)死亡。两名患者的死因是心肌梗死,两名患者是中风,一名患者是乳腺癌;其余七名患者的死因未确定:结论:鉴于 GCA 患者病情恶化的频率很高,需要对其进行长期随访,尤其是在确诊后的第一年。
{"title":"Clinical Manifestations and Prognosis of Giant Cell Arteritis: A Retrospective Cohort Study","authors":"E. E. Fedorinova,&nbsp;N. M. Bulanov,&nbsp;A. D. Meshkov,&nbsp;O. O. Borodin,&nbsp;I. O. Smitienko,&nbsp;E. V. Chachilo,&nbsp;A. A. Nartov,&nbsp;A. L. Filatova,&nbsp;A. V. Naumov,&nbsp;P. I. Novikov,&nbsp;S. V. Moiseev","doi":"10.1134/S1607672924700984","DOIUrl":"10.1134/S1607672924700984","url":null,"abstract":"<p>The aim of the study was to evaluate the clinical manifestations and survival of patients with giant cell arteritis (GCA).</p><p><b>.</b> A retrospective study included 166 patients with newly diagnosed GCA. Clinical, laboratory, and instrumental data and three sets of classification criteria were used to confirm the diagnosis: the American College of Rheumatology (ACR) 1990, the revised ACR criteria of 2016 and/or the new ACR and European Alliance of Rheumatologic Associations (EULAR) 2022 criteria. Some of the patients underwent instrumental investigations: temporal artery ultrasound Doppler (<i>n</i> = 61), contrast-enhanced computed tomography (<i>n</i> = 5), CT angiography (<i>n</i> = 6), magnetic resonance imaging (<i>n</i> = 4), MR angiography (<i>n</i> = 3), and 18F-FDG PET/CT (<i>n</i> = 47). Overall and recurrence-free survival rates were analyzed using survival tables and Kaplan–Meier method.</p><p><b>.</b> The most frequent first manifestations of GCA were headache (81.8%), weakness (64%), fever (63.8%), and symptoms of rheumatic polymyalgia (56.6%). Changes in temporal arteries in color duplex scanning were detected in 44 out of 61 patients. GCs therapy was performed in all patients who agreed to be treated (<i>n</i> = 158), methotrexate was used in 49 out of 158 patients, leflunomide in 9 patients. In 45 (28.5%) out of 158 patients, a stable remission was achieved as a result of GC monotherapy; in 120 (75.9%) patients, long-term maintenance therapy with GCs was required to prevent exacerbations, including 71 (44.9%) patients in combination with methotrexate or other immunosuppressive drugs. The follow-up period of patients with a history of relapses was 21.0 (8.0–54.0) months. Relapses developed in 73 (46.2%) patients. The overall one-year survival rate was 97.1% [95% CI 94.3; 99.9], and the five-year survival rate of patients was 94.6% [95% CI 90.2; 99.0]. The one-year relapse-free survival rate was 86.4% [95% CI 80.5; 92.3], and the five-year relapse-free survival rate was 52.4% [95% CI 42.0; 62.8]. Twelve (7.2%) of 166 patients died. The cause of death was myocardial infarction in two patients, stroke in two patients, and breast cancer in one patient; in the remaining seven cases, the cause of death was not determined.</p><p>Given the high frequency of disease exacerbation, patients with GCA require long-term follow-up, especially during the first year after diagnosis.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Homeotic DUX4 Genes Shape Dynamic Inter-Chromosomal Contacts with Nucleoli in Human Cells 同源 DUX4 基因在人类细胞中形成染色体间与核小体的动态联系
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-13 DOI: 10.1134/S1607672924700935
E. S. Klushevskaya, I. R. Alembekov, Y. V. Kravatsky, N. A. Tchurikov

Nucleoli form interchromosomal contacts with genes controlling differentiation and carcinogenesis. DUX4 genes specify transcription factor possessing two homeodomains. Previously, using Circular Chromosome Conformation Capture (4С) approach on population of cells, it was demonstrated that DUX4 gene clusters form frequent contacts with nucleoli. It was found also that these contacts are almost completely abolished after heat shock treatment. 4C approach as all ligation-mediated methods is capable to detect rather close interactions between chromatin loops in nuclei. In order to independently confirm the formation and the frequency of the contacts in single cells we used FISH approach. Here, we show that DUX genes in single cells form stable contacts in all tested HEK293T cells. During heat shock, DUX4 genes reversibly move 1–3 µm away from the nuclei. We conclude that interchromosomal contacts formed by nucleoli are strong, dynamic, and reversible, providing both the initiation and maintenance of a differentiated state.

核小体与控制分化和癌变的基因形成染色体间的联系。DUX4 基因指定了具有两个同源结构域的转录因子。此前,研究人员利用环状染色体构象捕获(4С)方法对细胞群进行了研究,结果表明 DUX4 基因簇与核小体形成频繁接触。研究还发现,这些接触在热休克处理后几乎完全消失。4C 方法与所有连接介导的方法一样,能够检测细胞核中染色质环之间相当密切的相互作用。为了独立确认单细胞中接触的形成和频率,我们使用了 FISH 方法。在这里,我们发现单细胞中的 DUX 基因在所有测试的 HEK293T 细胞中都形成了稳定的接触。在热休克过程中,DUX4 基因会可逆地远离细胞核 1-3 µm。我们的结论是,核小体形成的染色体间接触是强大、动态和可逆的,可启动和维持分化状态。
{"title":"Homeotic DUX4 Genes Shape Dynamic Inter-Chromosomal Contacts with Nucleoli in Human Cells","authors":"E. S. Klushevskaya,&nbsp;I. R. Alembekov,&nbsp;Y. V. Kravatsky,&nbsp;N. A. Tchurikov","doi":"10.1134/S1607672924700935","DOIUrl":"10.1134/S1607672924700935","url":null,"abstract":"<p>Nucleoli form interchromosomal contacts with genes controlling differentiation and carcinogenesis. <i>DUX4</i> genes specify transcription factor possessing two homeodomains. Previously, using Circular Chromosome Conformation Capture (4С) approach on population of cells, it was demonstrated that <i>DUX4</i> gene clusters form frequent contacts with nucleoli. It was found also that these contacts are almost completely abolished after heat shock treatment. 4C approach as all ligation-mediated methods is capable to detect rather close interactions between chromatin loops in nuclei. In order to independently confirm the formation and the frequency of the contacts in single cells we used FISH approach. Here, we show that <i>DUX</i> genes in single cells form stable contacts in all tested HEK293T cells. During heat shock, <i>DUX4</i> genes reversibly move 1–3 µm away from the nuclei. We conclude that interchromosomal contacts formed by nucleoli are strong, dynamic, and reversible, providing both the initiation and maintenance of a differentiated state.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Basic Fibroblast Growth Factor Accumulation in Culture Medium Masks the Direct Antitumor Effect of Anti-VEGF Agent Bevacizumab 培养基中碱性成纤维细胞生长因子的积累掩盖了抗血管内皮生长因子药物贝伐珠单抗的直接抗肿瘤作用
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-13 DOI: 10.1134/S1607672924600283
Zhiyong Wang, Ziyi Wang, Liyan Deng, Xiaolan Wu, Yanfang Liang, Pei Wei

The direct antitumor effect of bevacizumab (BEV) has long been debated. Evidence of the direct antitumor activities of drugs are mainly obtained from in vitro experiments, which are greatly affected by experimental conditions. In this study, we evaluated the effect of BEV-containing medium renewal on the results of in vitro cytotoxicity experiments in A549 and U251 cancer cells. We observed starkly different results between the experiments with and without BEV-containing medium renewal. Specifically, BEV inhibited the tumor cell growth in the timely replacement with a BEV-containing medium but promoted tumor cell growth without medium renewal. Meanwhile, compared with the control, a significant basic fibroblast growth factor (bFGF) accumulation in the supernatant was observed in the group without medium renewal but none in that with replaced medium. Furthermore, bFGF neutralization partially reversed the pro-proliferative effect of BEV in the medium non-renewed group, while exogenous bFGF attenuated the tumor cell growth inhibition of BEV in the medium-renewed group. Our data explain the controversy over the direct antitumor effect of BEV in different studies from the perspective of the compensatory autocrine cytokines in tumor cells.

贝伐单抗(BEV)的直接抗肿瘤作用一直存在争议。药物直接抗肿瘤活性的证据主要来自体外实验,而体外实验受实验条件的影响很大。在本研究中,我们评估了含有 BEV 的培养基更新对 A549 和 U251 癌细胞体外细胞毒性实验结果的影响。我们观察到,含 BEV 培养基更新和不含 BEV 培养基更新的实验结果截然不同。具体来说,在及时更换含 BEV 的培养基的情况下,BEV 可抑制肿瘤细胞的生长,但在不更换培养基的情况下,BEV 可促进肿瘤细胞的生长。同时,与对照组相比,未更新培养基组上清液中碱性成纤维细胞生长因子(bFGF)明显累积,而更换培养基组上清液中无累积。此外,在不更新培养基组中,bFGF 中和可部分逆转 BEV 的促增殖作用,而在更新培养基组中,外源性 bFGF 可减轻 BEV 对肿瘤细胞生长的抑制作用。我们的数据从肿瘤细胞代偿性自分泌细胞因子的角度解释了不同研究中对BEV直接抗肿瘤作用的争议。
{"title":"Basic Fibroblast Growth Factor Accumulation in Culture Medium Masks the Direct Antitumor Effect of Anti-VEGF Agent Bevacizumab","authors":"Zhiyong Wang,&nbsp;Ziyi Wang,&nbsp;Liyan Deng,&nbsp;Xiaolan Wu,&nbsp;Yanfang Liang,&nbsp;Pei Wei","doi":"10.1134/S1607672924600283","DOIUrl":"10.1134/S1607672924600283","url":null,"abstract":"<p>The direct antitumor effect of bevacizumab (BEV) has long been debated. Evidence of the direct antitumor activities of drugs are mainly obtained from in vitro experiments, which are greatly affected by experimental conditions. In this study, we evaluated the effect of BEV-containing medium renewal on the results of in vitro cytotoxicity experiments in A549 and U251 cancer cells. We observed starkly different results between the experiments with and without BEV-containing medium renewal. Specifically, BEV inhibited the tumor cell growth in the timely replacement with a BEV-containing medium but promoted tumor cell growth without medium renewal. Meanwhile, compared with the control, a significant basic fibroblast growth factor (bFGF) accumulation in the supernatant was observed in the group without medium renewal but none in that with replaced medium. Furthermore, bFGF neutralization partially reversed the pro-proliferative effect of BEV in the medium non-renewed group, while exogenous bFGF attenuated the tumor cell growth inhibition of BEV in the medium-renewed group. Our data explain the controversy over the direct antitumor effect of BEV in different studies from the perspective of the compensatory autocrine cytokines in tumor cells.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Prevalence and Factors Associated with Coronary Heart Disease in Patients with Gout 痛风患者冠心病的患病率及相关因素
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-13 DOI: 10.1134/S1607672924700972
E. L. Markelova, M. S. Eliseev, E. V. Il’inykh, S. I. Glukhova,  E. L. Nasonov

Gout is associated with increased risk of cardiovascular disease (CVD) morbidity and mortality. Therefore, an association between coronary heart disease (CHD) and gout deserves careful examination.

. The aim of this study was to determine the prevalence of CHD and factors associated with CHD in patients (pts) with gout.

. The study involved 286 male patients with gout, age 51.2 [42.8; 59.4] years (ys), disease duration 6.2 [3.8; 12.1] ys. All patients underwent standard clinical examination screening traditional risk factors (TRFs) of CVDs. We estimated the adjusted odds ratio (OR) and 95% confidence interval (95% CI).

. CHD was found in 111 out of the 286 pts (38.8%), MI had a history in 29.7%. Compared to individuals with CHD, participants without CHD were older (56.7[52.1; 61.1] vs 46.2[40.6; 53.4] ys), had longer duration of gout (9.3[4.7; 15.1] vs 5.6[3.3; 9.7] ys) (for all p < 0.05). Abdominal obesity (OR, 3.6; 95% CI, 1.2–10.9), family history of CHD (OR, 2.2; 95% CI, 1.3–3.7), disease duration of gout more 10 ys (OR, 2.8; 95% CI, 1.6–4.7), age of gout onset < 35 ys (OR, 5.5; 95% CI, 2.6–11.7), intraosseous tophi (OR, 3.03; 95% CI, 1.8–5.01), nephrolithiasis (OR, 1.7; 95% CI, 1.04–3.04), renal failure (OR, 5.6; 95% CI, 2.7–11.4), serum total cholesterol (TC), (OR, 1.6; 95% CI, 1.0–2.8), serum creatinine (OR, 2.5; 95% CI, 1.2–5.1), increased the risk for CHD in patients with a gout.

. The prevalence of CHD was 38.8% among individuals with gout (one-third of patients had a history of MI 29.7%). Our study showed that both TRFs of CVD and the severity of gout and a history of renal failure contribute to the development of CHD in patients with gout.

痛风会增加心血管疾病(CVD)的发病率和死亡率。因此,冠心病(CHD)与痛风之间的关联值得仔细研究。本研究旨在确定痛风患者(pts)中冠心病的患病率以及与冠心病相关的因素。研究涉及 286 名男性痛风患者,年龄 51.2 [42.8; 59.4] 岁,病程 6.2 [3.8; 12.1] 年。所有患者均接受了标准临床检查,筛查了心血管疾病的传统危险因素(TRFs)。我们估算了调整后的几率比(OR)和 95% 置信区间(95% CI)。286名患者中有111人(38.8%)患有冠心病,29.7%的患者有心肌梗死病史。与患有冠心病的患者相比,未患冠心病的患者年龄更大(56.7[52.1; 61.1] vs 46.2[40.6; 53.4]岁),痛风持续时间更长(9.3[4.7; 15.1] vs 5.6[3.3; 9.7]岁)(P均小于0.05)。01)、肾结石(OR,1.7;95% CI,1.04-3.04)、肾功能衰竭(OR,5.6;95% CI,2.7-11.4)、血清总胆固醇(TC)(OR,1.6;95% CI,1.0-2.8)、血清肌酐(OR,2.5;95% CI,1.2-5.1)会增加痛风患者罹患冠心病的风险。痛风患者的冠心病发病率为 38.8%(三分之一的患者有心肌梗死病史,占 29.7%)。我们的研究表明,心血管疾病的TRFs和痛风的严重程度以及肾功能衰竭史都会导致痛风患者罹患冠心病。
{"title":"The Prevalence and Factors Associated with Coronary Heart Disease in Patients with Gout","authors":"E. L. Markelova,&nbsp;M. S. Eliseev,&nbsp;E. V. Il’inykh,&nbsp;S. I. Glukhova,&nbsp; E. L. Nasonov","doi":"10.1134/S1607672924700972","DOIUrl":"10.1134/S1607672924700972","url":null,"abstract":"<p>Gout is associated with increased risk of cardiovascular disease (CVD) morbidity and mortality. Therefore, an association between coronary heart disease (CHD) and gout deserves careful examination.</p><p><b>.</b> The aim of this study was to determine the prevalence of CHD and factors associated with CHD in patients (pts) with gout.</p><p><b>.</b> The study involved 286 male patients with gout, age 51.2 [42.8; 59.4] years (ys), disease duration 6.2 [3.8; 12.1] ys. All patients underwent standard clinical examination screening traditional risk factors (TRFs) of CVDs. We estimated the adjusted odds ratio (OR) and 95% confidence interval (95% CI).</p><p><b>.</b> CHD was found in 111 out of the 286 pts (38.8%), MI had a history in 29.7%. Compared to individuals with CHD, participants without CHD were older (56.7[52.1; 61.1] vs 46.2[40.6; 53.4] ys), had longer duration of gout (9.3[4.7; 15.1] vs 5.6[3.3; 9.7] ys) (for all <i>p</i> &lt; 0.05). Abdominal obesity (OR, 3.6; 95% CI, 1.2–10.9), family history of CHD (OR, 2.2; 95% CI, 1.3–3.7), disease duration of gout more 10 ys (OR, 2.8; 95% CI, 1.6–4.7), age of gout onset &lt; 35 ys (OR, 5.5; 95% CI, 2.6–11.7), intraosseous tophi (OR, 3.03; 95% CI, 1.8–5.01), nephrolithiasis (OR, 1.7; 95% CI, 1.04–3.04), renal failure (OR, 5.6; 95% CI, 2.7–11.4), serum total cholesterol (TC), (OR, 1.6; 95% CI, 1.0–2.8), serum creatinine (OR, 2.5; 95% CI, 1.2–5.1), increased the risk for CHD in patients with a gout.</p><p><b>.</b> The prevalence of CHD was 38.8% among individuals with gout (one-third of patients had a history of MI 29.7%). Our study showed that both TRFs of CVD and the severity of gout and a history of renal failure contribute to the development of CHD in patients with gout.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Induction of the PERK-eIF2α-ATF4 Pathway in M1 Macrophages under Endoplasmic Reticulum Stress 内质网应激下诱导 M1 巨噬细胞中的 PERK-eIF2α-ATF4 通路
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-13 DOI: 10.1134/S1607672924600301
O. E. Kolodeeva, O. E. Kolodeeva, D. A. Averinskaya, Yu. A. Makarova

Translation inhibition can activate two cell death pathways. The first pathway is activated by translational aberrations, the second by endoplasmic reticulum (ER) stress. In this work, the effect of ribosome-inactivating protein type II (RIP-II) viscumin on M1 macrophages derived from the THP-1 cell line was investigated. The number of modified ribosomes was evaluated by real-time PCR. Transcriptome analysis revealed that viscumin induces the ER stress activated by the PERK sensor.

翻译抑制可激活两种细胞死亡途径。第一种途径由翻译畸变激活,第二种途径由内质网(ER)应激激活。本研究调查了核糖体灭活蛋白 II 型(RIP-II)粘蛋白对源自 THP-1 细胞系的 M1 巨噬细胞的影响。实时 PCR 评估了修饰核糖体的数量。转录组分析表明,粘蛋白可诱导由 PERK 传感器激活的 ER 应激。
{"title":"Induction of the PERK-eIF2α-ATF4 Pathway in M1 Macrophages under Endoplasmic Reticulum Stress","authors":"O. E. Kolodeeva,&nbsp;O. E. Kolodeeva,&nbsp;D. A. Averinskaya,&nbsp;Yu. A. Makarova","doi":"10.1134/S1607672924600301","DOIUrl":"10.1134/S1607672924600301","url":null,"abstract":"<p>Translation inhibition can activate two cell death pathways. The first pathway is activated by translational aberrations, the second by endoplasmic reticulum (ER) stress. In this work, the effect of ribosome-inactivating protein type II (RIP-II) viscumin on M1 macrophages derived from the THP-1 cell line was investigated. The number of modified ribosomes was evaluated by real-time PCR. Transcriptome analysis revealed that viscumin induces the ER stress activated by the PERK sensor.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11263228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-Carbamylated Protein Antibodies in ACPA-Negative and ACPA-Positive Patients with Rheumatoid Arthritis 类风湿性关节炎 ACPA 阴性和 ACPA 阳性患者的抗卡巴米蛋白抗体。
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-13 DOI: 10.1134/S1607672924700960
D. A. Dibrov, A. S. Avdeeva, M. E. Diatroptov,  E. L. Nasonov

The objective of this study was to assess the level of antibodies to carbamylated proteins and analyze the clinical and immunological associations in patients with ACPA-negative and ACPA-positive variants of rheumatoid arthritis.

. The study involved 150 patients with a reliable diagnosis of rheumatoid arthritis and 25 patients as healthy controls. Depending on ACPA values, two groups of patients were recruited: ACPA-positive (n = 75) and ACPA-negative (n = 75). RA activity was assessed by the DAS28 index. Determination of antibodies to carbamylated proteins was performed by enzyme-linked immunosorbent assay (BlueGene Biotech, China). Quantitative determination of ACPA in serum was performed by enzyme immunoassay using a commercial reagent kit (AxisShield, UK; upper limit of normal 5.0 U/mL; Orgentec, Germany; upper limit of normal 20.0 U/mL).

. Median anti-CarP in patients with RA was 126.2 [100.83; 157.41] ng/mL and was statistically significantly higher (p < 0.001) than in healthy controls (88.89 [70.53; 107.75] ng/mL). Among all patients with RA, 50 (33.3%) were anti-Carp-positive (22 (29.3%) in the ACPA(+) group and 28 (37.3%) in the ACPA(–) group), and one (2%) volunteer from healthy controls was anti-CarP(+) (p = 0.002). In ROC analysis performed to assess the diagnostic significance of anti-CarP for RA for all patients with RA, the area under the curve was 0.783 ± 0.047 with 95% CI: 0.691–0.874 (p < 0.001), with a cut-off point of 143 ng/mL, specificity 96%, sensitivity 36.7%.

In the ACPA(+) RA group, the erosion count was statistically significantly higher (p = 0.044) in anti-CarP(+) patients than in anti-CarP(–) patients. A weak direct correlation between anti-CarP and DAS28 was found in the ACPA(–) RA group.

. We studied the predictive value of anti-CarP as an auxiliary biomarker in ACPA(+) and ACPA(–) subtypes of RA. ACPA(+) anti-CarP(+) patients have a more “erosive” subtype of the disease than ACPA(+) anti-CarP(–) patients. In ACPA(–) patients, anti-CarP helps to identify a more erosive subtype of the disease, and among ACPA(–) patients it helps to reduce the proportion of seronegative patients. Further studies are required to determine the optimal standards for the laboratory diagnosis of anti-CarP and to clarify the diagnostic potential of these ABs as part of the differential diagnosis of arthritis in other rheumatic diseases.

本研究的目的是评估氨甲酰化蛋白抗体的水平,并分析 ACPA 阴性和 ACPA 阳性变异型类风湿性关节炎患者的临床和免疫学关联。研究涉及 150 名确诊为类风湿性关节炎的患者和 25 名健康对照组患者。根据 ACPA 值的不同,招募了两组患者:ACPA阳性(75人)和ACPA阴性(75人)。通过 DAS28 指数评估 RA 活性。氨甲酰化蛋白抗体的测定采用酶联免疫吸附试验(中国蓝基因生物技术有限公司)。血清中 ACPA 的定量检测采用酶联免疫法,使用商品试剂盒(AxisShield,英国;正常上限 5.0 U/mL;Orgentec,德国;正常上限 20.0 U/mL)。RA 患者抗 CarP 中位数为 126.2 [100.83; 157.41] ng/mL,在统计学上显著高于健康对照组(88.89 [70.53; 107.75] ng/mL)(p < 0.001)。在所有RA患者中,有50人(33.3%)抗Carp阳性(ACPA(+)组22人(29.3%),ACPA(-)组28人(37.3%)),健康对照组有1名志愿者(2%)抗CarP(+)(p = 0.002)。为评估抗 CarP 对所有 RA 患者的诊断意义而进行的 ROC 分析显示,曲线下面积为 0.783 ± 0.047,95% CI:0.691-0.874(p < 0.001),临界点为 143 ng/mL,特异性为 96%,敏感性为 36.7%。在ACPA(+)RA组中,抗CarP(+)患者的侵蚀计数在统计学上明显高于抗CarP(-)患者(p = 0.044)。在 ACPA(-)RA 组中,抗 CarP 与 DAS28 之间存在微弱的直接相关性。我们研究了抗 CarP 作为辅助生物标记物在 ACPA(+)和 ACPA(-)亚型 RA 中的预测价值。与ACPA(+)抗CarP(-)患者相比,ACPA(+)抗CarP(-)患者的疾病亚型更具 "侵蚀性"。在 ACPA(-)患者中,抗 CarP 有助于识别侵蚀性更强的疾病亚型,而在 ACPA(-)患者中,抗 CarP 有助于降低血清阴性患者的比例。还需要进一步研究来确定抗 CarP 实验室诊断的最佳标准,并明确这些 ABs 作为其他风湿性疾病关节炎鉴别诊断的一部分所具有的诊断潜力。
{"title":"Anti-Carbamylated Protein Antibodies in ACPA-Negative and ACPA-Positive Patients with Rheumatoid Arthritis","authors":"D. A. Dibrov,&nbsp;A. S. Avdeeva,&nbsp;M. E. Diatroptov,&nbsp; E. L. Nasonov","doi":"10.1134/S1607672924700960","DOIUrl":"10.1134/S1607672924700960","url":null,"abstract":"<p>The objective of this study was to assess the level of antibodies to carbamylated proteins and analyze the clinical and immunological associations in patients with ACPA-negative and ACPA-positive variants of rheumatoid arthritis.</p><p>. The study involved 150 patients with a reliable diagnosis of rheumatoid arthritis and 25 patients as healthy controls. Depending on ACPA values, two groups of patients were recruited: ACPA-positive (<i>n</i> = 75) and ACPA-negative (<i>n</i> = 75). RA activity was assessed by the DAS28 index. Determination of antibodies to carbamylated proteins was performed by enzyme-linked immunosorbent assay (BlueGene Biotech, China). Quantitative determination of ACPA in serum was performed by enzyme immunoassay using a commercial reagent kit (AxisShield, UK; upper limit of normal 5.0 U/mL; Orgentec, Germany; upper limit of normal 20.0 U/mL).</p><p>. Median anti-CarP in patients with RA was 126.2 [100.83; 157.41] ng/mL and was statistically significantly higher (<i>p</i> &lt; 0.001) than in healthy controls (88.89 [70.53; 107.75] ng/mL). Among all patients with RA, 50 (33.3%) were anti-Carp-positive (22 (29.3%) in the ACPA(+) group and 28 (37.3%) in the ACPA(–) group), and one (2%) volunteer from healthy controls was anti-CarP(+) (<i>p</i> = 0.002). In ROC analysis performed to assess the diagnostic significance of anti-CarP for RA for all patients with RA, the area under the curve was 0.783 ± 0.047 with 95% CI: 0.691–0.874 (<i>p</i> &lt; 0.001), with a cut-off point of 143 ng/mL, specificity 96%, sensitivity 36.7%.</p><p>In the ACPA(+) RA group, the erosion count was statistically significantly higher (<i>p</i> = 0.044) in anti-CarP(+) patients than in anti-CarP(–) patients. A weak direct correlation between anti-CarP and DAS28 was found in the ACPA(–) RA group.</p><p>. We studied the predictive value of anti-CarP as an auxiliary biomarker in ACPA(+) and ACPA(–) subtypes of RA. ACPA(+) anti-CarP(+) patients have a more “erosive” subtype of the disease than ACPA(+) anti-CarP(–) patients. In ACPA(–) patients, anti-CarP helps to identify a more erosive subtype of the disease, and among ACPA(–) patients it helps to reduce the proportion of seronegative patients. Further studies are required to determine the optimal standards for the laboratory diagnosis of anti-CarP and to clarify the diagnostic potential of these ABs as part of the differential diagnosis of arthritis in other rheumatic diseases.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Doklady Biochemistry and Biophysics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1